Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bristol-Myers Squibb (NY: BMY ) 49.74 +0.25 (+0.51%) Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Bristol-Myers Squibb < Previous 1 2 3 4 5 6 7 8 9 ... 63 64 Next > Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy Today 9:53 EDT Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients. Via Benzinga New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis Today 6:59 EDT From Bristol Myers Squibb Via Business Wire What Analysts Are Saying About Bristol-Myers Squibb Stock September 16, 2024 Via Benzinga 3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade September 16, 2024 Now could be a great time to scoop up three stocks trading way below their previous peaks. Via The Motley Fool Current Report: Bristol-Meyers Squibb (BMY) September 16, 2024 The most recent $0.60 Q dividend was declared September 10th for shareholders of record October 4th and is payable November 1st. There’s time to fetch this payout! Via Talk Markets Market Whales and Their Recent Bets on BMY Options August 27, 2024 Via Benzinga Merck Scores Two Key Victories With Keytruda In Women's Cancers September 15, 2024 The company also unveiled 10-year test results for Keytruda in advanced melanoma patients. Via Investor's Business Daily Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma September 15, 2024 From Bristol Myers Squibb Via Business Wire Got $200? 2 Healthcare Stocks to Buy and Hold Forever September 14, 2024 These two stocks have had their issues in recent years, but both look like reliable long-term bets. Via The Motley Fool Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 September 12, 2024 From Bristol Myers Squibb Via Business Wire Bristol Myers Squibb Announces Dividend September 10, 2024 From Bristol Myers Squibb Via Business Wire Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' September 09, 2024 Via Benzinga Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... Via Benzinga Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms September 09, 2024 From Bristol Myers Squibb Via Business Wire 2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 September 08, 2024 These dividend payers could more than double their payouts in the decade ahead. Via The Motley Fool FDA Battles Backlog of Drug Factory Inspections Since COVID-19 September 06, 2024 FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. Via Benzinga Exposures Product Safety Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research September 06, 2024 From Bristol Myers Squibb Via Business Wire Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs September 03, 2024 Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... Via Benzinga Topics Economy Exposures Interest Rates 2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High September 02, 2024 Rebounding growth could make shares of this leading drugmaker a big winner. Via The Motley Fool 2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now September 01, 2024 No stock is perfect, but quality businesses can stand the test of time in your portfolio. Via The Motley Fool Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) September 01, 2024 From Bristol Myers Squibb Via Business Wire Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review August 30, 2024 The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. Via Investor's Business Daily Topics Stocks Exposures US Equities Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet August 30, 2024 The Benzinga Stock Whisper Index looks at five stocks seeing above average interest from investors during the week. Via Benzinga As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors August 28, 2024 Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. Via Benzinga Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday August 28, 2024 Via Benzinga Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers August 28, 2024 As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. Via Investor's Business Daily 3 High-Yield Dividend Stocks With Payout Ratios Below 75% August 28, 2024 Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses. Via The Motley Fool 2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever August 28, 2024 These underappreciated dividend payers offer yields above 4% at recent prices. Via The Motley Fool Topics Stocks Exposures US Equities Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna August 27, 2024 Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 63 64 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.